Lushang Freda Pharmaceutical Co.,Ltd.

600223

CNE000001147

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
7.89 ^CNY	-5.96%		-3.07%	-18.07%

Apr. 29	Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Lushang Health Industry Development Co.,Ltd. cancelled the acquisition of an unknown minority stake in Shandong Focuschem Biotech Co., Ltd.

October 30, 2020

Lushang Health Industry Development Co.,Ltd. (SHSE:600223) agreed to acquire unknown minority stake in Shandong Focuschem Biotech Co., Ltd. on October 1, 2019. The Board of Directors of Lushang Health Industry Development Co.,Ltd. approved the deal. Lushang Health Industry Development Co.,Ltd. (SHSE:600223) cancelled the acquisition of an unknown minority stake in Shandong Focuschem Biotech Co., Ltd. on October 1, 2020.

Latest news about Lushang Freda Pharmaceutical Co.,Ltd.

Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Lushang Life Services Co., Ltd. agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. for CNY 4.9 million.	Feb. 26	CI
Lushang Health Industry to Sell 90% Stake in Healthcare Subsidiary for 21 Million Yuan	Dec. 13	MT
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-12	CI
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Lushang Health Industry Plans Selling Real Estate Assets to Controlling Shareholder	22-11-16	MT
Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates	22-11-15	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Lushang Life Chairman Steps Down	22-08-26	MT
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Lushang Life Shares Slump 15% at Open, Joins Wave of Lackluster Hong Kong Debutants	22-07-07	MT
Lushang Development's Property Manager Arm Raises Nearly $18 Million in Hong Kong IPO	22-07-07	MT
Lushang Development's Property Manager Arm Launches Up to $34 Million Hong Kong IPO	22-06-26	MT
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-22	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-26	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-26	CI
Lushang Health Industry Development Co.,Ltd. cancelled the acquisition of an unknown minority stake in Shandong Focuschem Biotech Co., Ltd.	20-09-30	CI
Lushang Health Industry Development Co.,Ltd.(XSSC:600223) added to S&P Global BMI Index	20-09-21	CI
Lushang Health Industry Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-25	CI

Chart Lushang Freda Pharmaceutical Co.,Ltd.

Duration

Period

Chart Lushang Freda Pharmaceutical Co.,Ltd.

More charts

Company Profile

Lushang Freda Pharmaceutical Co Ltd is a China-based company mainly engaged in the manufacture and sale of pharmaceuticals and cosmetics. In terms of medicine, the Company is committed to the research and development, production and sales of Chinese patent medicines, chemical medicines, and health foods. Its products cover five fields: orthopedics, gynecology, internal medicine, ophthalmology, and pediatrics. The Company's cosmetic products involve aroma therapy, aroma skin care, aroma health care, aroma health care and other fields. In terms of raw materials, derivative products, and additives, the Company is mainly engaged in the production of hyaluronic acid raw materials.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lushang Freda Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.89 CNY

Average target price

11.78 CNY

Spread / Average Target

+49.37%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUSHANG FREDA PHARMACEUTICAL CO.,LTD.	-18.07%	1.11B
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B

Other Pharmaceuticals

Lushang Freda Pharmaceutical Co.,Ltd.

Equities

600223

CNE000001147

Pharmaceuticals

Lushang Health Industry Development Co.,Ltd. cancelled the acquisition of an unknown minority stake in Shandong Focuschem Biotech Co., Ltd.

Latest news about Lushang Freda Pharmaceutical Co.,Ltd.

Chart Lushang Freda Pharmaceutical Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for Lushang Freda Pharmaceutical Co.,Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals